Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma

Inclusion Criteria:

* Histologically or cytologically documented malignancy (solid tumor or lymphoma)
* Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2
* Predicted life expectancy of at least 3 months
* Adequate hematopoietic and hepatic function, and normal renal function
* Fasting glucose \<7mmol/L at baseline
* Left ventricular ejection fracture (LVEF) by Multiple gated acquisition scan (MUGA)≥ 60%
* Practice effective contraceptive measures throughout study
* Verbal and written informed consent
* Prior therapy:

  * Chemotherapy, minimum of 3 weeks and recovered from any treatment-related toxicities (except for alopecia, and grade 1 neurotoxicity) prior to registration
  * Hormonal, discontinued prior to registration
  * Radiation, minimum of 21 days and recovered from toxic effects prior to registration
  * Surgery, provided wound healing has occurred

Exclusion Criteria:

* History of significant cardiac disease unless well controlled
* Discontinuation from prior therapy due to cardiac toxicity
* Active or uncontrolled infections
* Serious illness or medical condition that could interfere with study participation
* History of any psychiatric condition that might impair understanding or compliance
* Documented history of diabetes mellitus
* Pregnant or breastfeeding females
* Unstable symptomatic brain metastases, that require steroid or that have required radiation in the last 28 days
* Chronic systemic steroid use for cancer related condition
* History of allergic reactions
* Patients with cataract who are expected to undergo surgery within 6 months of registration
* Use of drugs causing QT interval prolongation within 14 days prior to dosing
* Patients with clinically significant electrolyte imbalances